Your browser doesn't support javascript.
loading
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Chatterjee, M; Turner, D C; Felip, E; Lena, H; Cappuzzo, F; Horn, L; Garon, E B; Hui, R; Arkenau, H-T; Gubens, M A; Hellmann, M D; Dong, D; Li, C; Mayawala, K; Freshwater, T; Ahamadi, M; Stone, J; Lubiniecki, G M; Zhang, J; Im, E; De Alwis, D P; Kondic, A G; Fløtten, Ø.
Afiliación
  • Chatterjee M; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Turner DC; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Felip E; Thoracic Tumors Group, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Lena H; Pneumonology Service, Centre Hospitalier Universitaire Rennes, Rennes, France.
  • Cappuzzo F; Department of Medical Oncology, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy.
  • Horn L; Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, USA.
  • Garon EB; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, USA.
  • Hui R; Department of Medical Oncology, Westmead Hospital and the University of Sydney, Sydney, Australia.
  • Arkenau HT; Department of Medical Oncology, Sarah Cannon Research Institute UK and University College London, London, UK.
  • Gubens MA; Department of Medicine, University of California, San Francisco, San Francisco.
  • Hellmann MD; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.
  • Dong D; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Li C; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Mayawala K; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Freshwater T; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Ahamadi M; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Stone J; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Lubiniecki GM; Oncology Clinical Research, Merck & Co., Inc., Kenilworth.
  • Zhang J; Biostatistics and Research Design Sciences, Merck & Co., Inc., Kenilworth, USA.
  • Im E; Oncology Clinical Research, Merck & Co., Inc., Kenilworth.
  • De Alwis DP; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Kondic AG; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, USA.
  • Fløtten Ø; Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway oystein.flotten@helse-bergen.no.
Ann Oncol ; 27(7): 1291-8, 2016 07.
Article en En | MEDLINE | ID: mdl-27117531
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pronóstico / Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pronóstico / Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos